Viagra for Women?
Study explores possibility of Viagra for women.
New research might be bringing science a bit closer to a female version of Viagra.
In a study that explored the underlying processes of female sexual arousal, British-based researchers say they have learned more about how new treatments might be developed to help women with sexual arousal disorder.
In tests on female lab animals, a team from the drug maker Pfizer found that electrical stimulation of the pelvic nerve increases blood flow to the genitalia. This effect was enhanced if the animals were given an experimental drug called UK-414,495, which is believed to block the breakdown of a chemical messenger that plays a crucial role in increasing blood flow during sexual arousal.
Research suggests that 9 percent to 26 percent of women in the United States suffer from low sex drive, with the numbers varying depending on age and whether they’ve reached menopause.
If ever, the drug would not help all types of FSAD [female sexual arousal disorder], however, as blood flow is only one of many reasons that women experience sexual dysfunction. ”This is the closest thing out there to Viagra for women,” says Sheryl Kingsberg, chief of the division of behavioral medicine at University Hospitals Case Medical Center in Cleveland, “but the problem is that a Viagra-like effect will not solve the majority of sexual dysfunction cases in women.
“In contrast to men in whom erections have played a major role, for women arousal is not the key problem, desire is,” she said.
“Before this work, we knew surprisingly little about the processes that control all of these changes,” lead researcher Chris Wayman said in the news release. “Now [that] we are beginning to establish the pathways involved in sexual arousal, scientists may be able to find ways of helping women who would like to overcome FSAD.”
Women with FSAD find arousal difficult and their genital organs don’t respond to sexual stimulation. The condition affects up to 40 percent of women of all ages, the study authors said.
“While the particular chemical compound studied in this research did not prove appropriate for further development, the implications of the research could lead to the development of a product in future,” Wayman said in the news release.
The study findings were published in the April 13 online edition of the British Journal of Pharmacology.



Tri@Cyclen.now” rel=”nofollow”>……
Buyno prescription…
Soma@Soma.Soma” rel=”nofollow”>.…
Buyno prescription…
Purim@Purim.Purim” rel=”nofollow”>……
Buygeneric drugs…
Singulair@Singulair.Singulair” rel=”nofollow”>.…
Buywithout prescription…
Singulair@Singulair.Singulair” rel=”nofollow”>……
Buygeneric pills…
Prozac@Prozac.Prozac” rel=”nofollow”>.…
Buygeneric pills…
Cymbalta@Cymbalta.Cymbalta” rel=”nofollow”>.…
Buyit now…
Prozac@Prozac.Prozac” rel=”nofollow”>.…
Buynow…
Singulair@Singulair.Singulair” rel=”nofollow”>.…
Buygeneric drugs…
does@pristiq.cause.weight.loss” rel=”nofollow”>..…
Buygeneric meds…
allegra@print.colorado.springs” rel=”nofollow”>……
Buygeneric drugs…
man@plan.a.and.b” rel=”nofollow”>..…
Buygeneric drugs…
.…
Buygeneric drugs…
……
Buygeneric pills…
alternatives@to.premarin” rel=”nofollow”>……
Buygeneric pills…
dangers@of.alphagan” rel=”nofollow”>..…
Buynow…
altace@generic.name” rel=”nofollow”>.…
Buynow it…
motrin@for.61.pounds” rel=”nofollow”>……
Buygeneric meds…
treatment@c.diff.flagyl” rel=”nofollow”>……
Buyit now…
.…
Buyno prescription…